Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Tyme Technologies, Inc. (NASDAQ: TYME).

Full DD Report for TYME

You must become a subscriber to view this report.


Recent News from (NASDAQ: TYME)

Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region
SOMERVILLE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Di...
Source: GlobeNewswire
Date: September, 11 2018 08:00
Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion of the Company’s Phase II trial in metastatic pa...
Source: GlobeNewswire
Date: September, 05 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-142.312.422.432.29270,866

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10148,042256,89457.6277Short
2018-12-07105,097201,66352.1152Short
2018-12-06227,977409,58455.6606Short
2018-12-04212,134405,71352.2867Short
2018-12-03359,394798,14545.0287Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TYME.


About Tyme Technologies, Inc. (NASDAQ: TYME)

Logo for Tyme Technologies, Inc. (NASDAQ: TYME)

TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in a metabolic approach to killing cancer and using the body s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body s immune system to fight a variety of cancers.

 

 

 

Current Management

  • Steven Hoffman / CEO
  • Michael Demurjian / COO
  • Tommy Thompson / Advisor
  • Michael Demurjian /
  • Steven Hoffman /
  • Gerald Sokol /
  • Timothy Tyson / Independent Director

Current Share Structure

  • Market Cap: $279,524,938 - 05/18/2018
  • Authorized: 300,000,000 - 03/05/2018
  • Issue and Outstanding: 90,902,419 - 03/05/2018
  • Float: 10,175,400 - 04/18/2016

 


Recent Filings from (NASDAQ: TYME)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 05 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 27 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: July, 31 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: July, 25 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: June, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 29 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 25 2018

 

 


Daily Technical Chart for (NASDAQ: TYME)

Daily Technical Chart for (NASDAQ: TYME)


Stay tuned for daily updates and more on (NASDAQ: TYME)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TYME)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TYME is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TYME and does not buy, sell, or trade any shares of TYME. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/